POAG surgical outcomes affected by DM

Article

According to recently published data, POAG patients with diabetes mellitus (DM) undergoing primary trabeculectomy with MMC do not achieve the same long-term IOP control compared to patients without DM.

According to recently published data, POAG patients with diabetes mellitus (DM) undergoing primary trabeculectomy with MMC do not achieve the same long-term IOP control compared to patients without DM.

Dr Simon K. Law, Glaucoma Division, Jules Stein Eye Institute, David Geffen School of Medicine, University of California Los Angeles, California, USA, studied 41 eyes of 29 patients with DM and 81 eyes of 64 patients without DM. Patients with DM without retinopathy were retrospectively compared with a control group without DM. Surgical success was defined as IOP ≤15 and >5 mmHg without complications or further glaucoma surgery.

At 60 months the Kaplan–Meier cumulative survival rates were 57.8±9.3% for the DM group and 68.6±5.3% for the control group. Mean postoperative IOP of the control group was statistically significantly lower than the DM group at the two, three, six and seven-year follow-up visits. The rates of postoperative complications and additional glaucoma surgeries were the same between the two groups.

POAG patients with DM without retinopathy undergoing primary trabeculectomy with MMC could have a lower long-term surgical survival rate, compared to patients without DM.

The abstract can be read in the latest issue of the British Journal of Ophthalmology.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.